Table 2.
Study group | Inclusion | Systemic therapy | Radiotherapy | Outcome |
---|---|---|---|---|
NCCTG [30] | 1–3 metastatic sites | Nonstandardized | 60 Gy (2 Gy fx) 45 Gy (3 Gy fx) |
Closed due to poor accrual |
University of Chicago [31] | 1–5 metastatic sites | Cisplatin docetaxel |
50 Gy (5 Gy fx) 60 Gy (2 Gy fx) if Combined with CT |
Closed due to poor accrual |
Wake Forest University [32] | Limited metastatic NSCLC | Non-standardized | HIGRT or conventional RT |
Open to accrual |